Abstract:Introduction: Cyclin D1 protein expression in lymphocytes is commonly associated with mantle cell lymphoma. However, it has rarely been reported in patients with diffuse large B-cell leukemia (DLBCL), particularly in Asia where studies on cyclin D1 expression in DLBCL are limited and often small. Furthermore, the clinical implications of cyclin D1 expression in Asia remain unclear. Methods: In this study, a total of 815 patients diagnosed with DLBCL and treated with R-CHOP or R-CHOP-like regimens over a five-year period were reviewed. The authors conducted clinical, immunohistochemical, and genetic analyses, with a specific focus on cyclin D1. Immunohistochemistry was used to identify cyclin D1-positive patients, and fluorescence in situ hybridization was employed to assess cyclin D1 gene (CCND1) rearrangements. A comparison was made between DLBCL patients with and without cyclin D1 expression in terms of clinical, immunohistochemical, and genetic features. Results: Among the DLBCL patients, 16 individuals (2.61%) exhibited cyclin D1 expression without CCND1 gene rearrangements. Cyclin D1-positive DLBCLs were observed in patients with a median age of 58.88 ± 4.07 years, with 93.75% of them classified as stage IV. The majority of cyclin D1-positive patients (81.25%) displayed elevated serum lactate dehydrogenase (LDH) levels and advanced international prognostic index (IPI) scores. Additionally, all cases exhibited a proliferation rate exceeding 80%, and a significant proportion (93.75%) demonstrated MYC expression. Cyclin D1-positive DLBCLs were associated with elevated LDH levels, higher IPI scores, advanced stage, increased Ki-67 proliferation, and MYC expression (p<0.05). However, no significant differences were observed in other clinical characteristics and immunohistochemical features. Patients with cyclin D1 expression experienced shorter progression-free survival (PFS) and overall survival (OS) compared to cyclin D1-negative patients (p<0.05). Next-generation sequencing (NGS) was performed to explore the molecular mechanisms underlying cyclin D1-positive DLBCL. Among the top 50 gene alterations identified, all samples exhibited BRD9 and NOTCH2NL gene mutations, while gene alterations in the PI3K/AKT signaling pathways were evident in cyclin D1-positive DLBCLs. Furthermore, a more pronounced variation in the MTOR gene was observed between cyclin D1-positive and negative patients. Notably, DLBCL patients with cyclin D1 expression frequently exhibited CDKN2A and CDKN2B gene deletions, known to regulate the cell cycle transition from G1 to S phase in tumors. Conclusion: Cyclin D1-positive DLBCL patients exhibited aggressive clinical behavior and inferior survival outcomes compared to DLBCL patients without cyclin D1 expression. NGS studies revealed a potential association between cyclin D1 expression and abnormal cell cycle transition and AKT pathway activation. These findings support the existence of a diagnostically challenging “gray zone” of DLBCL associated with cyclin D1 expression.

Expression and Significance of Cyclin-Dependent Protein Kinase 6 in Diffuse Large B-Cell Lymphoma.

Increased Cyclin-Dependent Kinase 6 Expression in Bladder Cancer

Clinical and Biological Significance of De Novo CD5+ Diffuse Large B-cell Lymphoma in Western Countries.

Dysregulated CXCR4 Expression Promotes Lymphoma Cell Survival and Independently Predicts Disease Progression in Germinal Center B-cell-like Diffuse Large B-cell Lymphoma.

[Prognostic Significance of Proteins Expression by Immunohistochemical Method in Diffuse Large B Cell Lymphoma].

CDC6, a key replication licensing factor, is overexpressed and confers poor prognosis in diffuse large B-cell lymphoma

CDK6 is a novel predictive and prognosis biomarker correlated with immune infiltrates in multiple human neoplasms, including small cell lung carcinoma

Cyclin D1-Positive Expression Associated with Prognostic Significance and Clinicopathological Characteristics By Paving the Way for Proliferation in Diffuse Large B-Cell Lymphomas

CCDC50, an Essential Driver Involved in Tumorigenesis, is a Potential Severity Marker of Diffuse Large B Cell Lymphoma

The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma.

Whole Transcriptome Data Analysis Reveals Prognostic Signature Genes for Overall Survival Prediction in Diffuse Large B Cell Lymphoma

CDK6 Is a Potential Prognostic Biomarker in Acute Myeloid Leukemia

Comprehensive analysis of the expression and significance of CXCLs in human diffuse large B-cell lymphoma

Analysis of Bcl-6 Protein Expression and Gene Rearrangement in Diffuse Large B-cell Lymphoma

PB2108: PREVALENCE AND CLINICAL IMPLICATIONS OF CYCLIN D1 POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA IN CHINA

Expression of Cyclin D2 and its clinicopathological significance in diffuse large B cell lymphoma

High expression of cell division cycle 7 protein correlates with poor prognosis in patients with diffuse large B-cell lymphoma

Activation and Clinicopathologic Significance of AKT/mTOR Signaling Pathway in Diffuse Large B-cell Lymphoma

The Prognostic Significance of CDK6 Expression in Renal Cell Carcinoma Treated by Immune Checkpoint Plus Tyrosine Kinase Inhibition.

CDK6 as a Biomarker for Immunotherapy, Drug Sensitivity, and Prognosis in Bladder Cancer: Bioinformatics and Immunohistochemical Analysis

Genomic Landscape of CDK6 Amplification and Its Potential Prognostic Value in Adult-Type Diffuse Gliomas.